The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global ulcerative colitis market reached a value of US$ 6.92 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 9.71 Billion by 2027, exhibiting a CAGR of 5.60% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Ulcerative colitis (UC) refers to a chronic inflammatory bowel disease (IBD) that causes irritation, inflammation, and ulcers (sores) in the digestive tract. It typically affects the inner lining of the large intestine (or colon) and rectum. The symptoms generally develop over time, and individuals diagnosed with UC may experience periods of mild or no symptoms. However, it can sometimes lead to debilitating or life-threatening complications. While there is no cure for UC yet, the treatment can help patients manage and reduce their symptoms, prevent flare-ups, and bring about long-term remission. As a result, UC treatment is rapidly gaining traction across the globe as it can help enhance the quality of life and ensure the physical and mental wellbeing of the patients.
The widespread prevalence of UC disease and the rising awareness regarding the available treatment options represent the primary factors driving the market growth. Besides this, the presence of strong pipeline products and continuous advancements in numerous drugs are augmenting the product demand. Additionally, governments of various countries are taking several initiatives to spread awareness about the condition and enhance the accessibility and availability of proper healthcare facilities. This, in confluence with the increasing investments in the research and development (R&D) activities for the development of novel therapies, is propelling the market growth. Furthermore, the leading players are focusing on launching innovative and more effective drugs to expand their product portfolio and gain a competitive edge in the market. Other factors, including the easy availability of biosimilar drugs, improving healthcare infrastructure, favorable reimbursement policies, and increasing consumer spending on healthcare, are also creating a positive market outlook.
IMARC Group provides an analysis of the key trends in each sub-segment of the global ulcerative colitis market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, disease type, molecule type, drug type, route of administration and distribution channel.
Breakup by Type:
Breakup by Disease Type:
Breakup by Molecule Type:
Breakup by Drug Type:
Breakup by Route of Administration:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.
|Base Year of the Analysis||2021|
|Segment Coverage||Type, Disease Type, Molecule Type, Drug Type, Route of Administration, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at